Status:
RECRUITING
Interstitial Lung Disease Trajectories in Patients With Systemic Sclerosis
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Systemic Sclerosis
Interstitial Lung Disease
Eligibility:
All Genders
18+ years
Brief Summary
Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. In patients with systemic sclerosis, interstitial lung disease (ILD) concerns alm...
Eligibility Criteria
Inclusion
- Patients with systemic sclerosis according to 2013 ACR/EULAR criteria
- Patients with interstitial lung disease on HRCT chest
- Patients with PFT at ILD diagnosis and at least 1 PFT evaluation during follow-up
Exclusion
- Patients with an alternative diagnosis of SSc-associated ILD (silicosis, sarcoidosis, lung cancer or other significant lung abnormalities)
Key Trial Info
Start Date :
May 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT05345795
Start Date
May 1 2023
End Date
September 1 2025
Last Update
August 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Nancy
Vandœuvre-lès-Nancy, Grand Est, France, 54500